(Total Views: 700)
Posted On: 02/05/2022 3:11:56 AM
Post# of 154001
Figgs posted an info sheet about our Brazil trial(s) that read in part:
What struck me about this was the last listing above: "Available for licensing -- Yes -- NASH"
Figgs, what was this listing and when was it filed? Just the fact that it describes NASH as "available for licensing" seems likely a potent clue to unlocking the riddle of the past several weeks at CYDY. Isn't that what is going on? Someone licensing the NASH indication?
Figgs, if you're there, tell us what this was -- where and when you got it? Thanks!
Quote:
Originator
Progenics Pharmaceuticals
Developer
Albert Einstein Israelite Hospital; CytoDyn; Progenics Pharmaceuticals
Class
Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
Mechanism of Action
CCR5 receptor antagonists; Virus internalisation inhibitors
Orphan Drug Status
Yes - Graft-versus-host disease
New Molecular Entity
Yes
Available For Licensing
Yes - Non-alcoholic steatohepatitis
What struck me about this was the last listing above: "Available for licensing -- Yes -- NASH"
Figgs, what was this listing and when was it filed? Just the fact that it describes NASH as "available for licensing" seems likely a potent clue to unlocking the riddle of the past several weeks at CYDY. Isn't that what is going on? Someone licensing the NASH indication?
Figgs, if you're there, tell us what this was -- where and when you got it? Thanks!
(5)
(0)
